We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI-Driven Blood Test to Revolutionize Diagnosis of Long COVID in Children

By LabMedica International staff writers
Posted on 29 Jan 2025

Long COVID affects about 0. More...

5% of pediatric patients exposed to SARS-CoV-2. Also known as post-COVID or post-acute sequelae of SARS-CoV-2, this condition is characterized by persistent symptoms that appear after the viral infection and last for at least 8-12 weeks, significantly impacting daily life. Long COVID has been observed across all age groups, with children over the age of 10 being particularly affected in terms of severity. While proteomic studies have highlighted a pro-inflammatory signature and thrombo-inflammation in adults with long COVID, similar findings had not been documented in the pediatric population. Now, a new method can accurately diagnose long COVID in children using a blood sample and artificial intelligence (AI).

In a study led by researchers at Università Cattolica del Sacro Cuore (UCSC, Milan, Italy) and associated institutions, an AI tool was found to effectively detect the molecular signature of long COVID in plasma samples from pediatric patients, with an accuracy rate of 93%. For their research, the team performed a detailed protein analysis on blood plasma from children under 19 years of age, comparing those with long COVID to control groups including children with acute COVID-19, MIS-C, and healthy controls. Children were classified as having long COVID if they experienced persistent symptoms for at least 8 weeks after the initial infection, which negatively impacted their daily activities and could not be attributed to other causes. The study included 112 children, with 34 meeting the clinical criteria for long COVID, 32 with acute SARS-CoV-2 infection, 27 with MIS-C, and 19 healthy controls.

The study, published in the journal Pediatric Research, showed that children with long COVID showed higher expression of a specific set of pro-inflammatory and pro-angiogenic chemokines (CXCL11, CXCL1, CXCL5, CXCL6, CXCL8, TNFSF11, OSM, STAMBP1a) compared to controls. Using a machine learning model based on this proteomic profile, researchers identified long COVID with an accuracy of 93%, a specificity of 86%, and a sensitivity of 97%. The findings indicate that pediatric long COVID is characterized by an increased blood protein signature associated with ongoing general and endothelial inflammation, similar to what has been observed in adults. This study is the first to document the pro-inflammatory profile in children with long COVID, and the results may contribute to the development of future diagnostic tests.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.